Sildodime M 25 tablet is a combination of a β3-adrenoceptor agonist (Mirabegron) and an alpha-1 blocker (Silodosin) used for managing overactive bladder and lower urinary tract symptoms associated with BPH.
It works by relaxing bladder and prostate smooth muscles, improving urinary flow, reducing urgency, frequency, and nocturia, and enhancing bladder control.
This tablet is widely prescribed in overactive bladder syndrome, benign prostatic hyperplasia, and urinary retention management, helping adult patients maintain better urinary comfort and daily convenience.
With strong clinical relevance in urology therapy, growing physician acceptance, and increasing demand in bladder and BPH management, this formulation strengthens institutional and outpatient therapy portfolios and supports sustained therapeutic utilization.
Some patients may experience headache, dizziness, mild gastrointestinal discomfort, increased blood pressure, or nasal congestion. Rarely, serious cardiovascular events, allergic reactions, or urinary retention may occur and should be reported to a healthcare professional immediately.
Sildodime M 25 Tablet is indicated for adult patients experiencing symptoms of overactive bladder, such as urinary urgency, increased frequency, and urge incontinence, especially when associated with benign prostatic hyperplasia. The combination of Mirabegron and Silodosin improves bladder storage, enhances urine flow, and provides comprehensive relief from bladder and prostate-related urinary issues.
This medicine should be used under medical supervision. Patients with severe hypertension, heart disease, liver or kidney impairment, or other urological conditions should consult their healthcare provider before use. Strict adherence to the prescribed dosage is essential for safe and effective therapy.
Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.